Latest news

Debiopharm presents phase I monthly implant and phase II daily oral results of ZT-1 for Alzheimer´s disease

Debiopharm S.A. presented results of a double-blind placebo-controlled study on first-in-class Debio-025 in HIV-1-infected subjects

Debiopharm and Dyax Corp. restructure development agreement for Depelestat (EPI-hNE4 or DX-890) in pulmonary disorders

Debiopharm and EPFL launch the “Debiopharm Life Sciences Award”

The Japanese Cancer Association (JCA) and Debiopharm present the inaugural 2005 JCA-Mauvernay award in Japan

Debiovision Inc., a speciality pharmaceutical developer joins the Debio companies

Debiopharm and DeveloGen announce partnering of myasthenia gravis program

Debiopharm and Neovacs sign License and Equity Agreement for the development fo Neovacs´ anti-TNF-Alpha product

Debiopharm announces marketing and supply agreement for Trelstar® in Canada